EP
CRSP icon

Eudaimonia Partners’s CRISPR Therapeutics CRSP Stock Holding History

Eudaimonia Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-254
Closed -$31K – 568
2021
Q1 		$31K Buy
+254
New +$38.4K 0.01% 794

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Eudaimonia Partners's CRSP Position: Q2 2021 in Review

Eudaimonia Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 254 shares — an estimated $31K sold.

Eudaimonia Partners first reported a position in CRSP in Q1 2021 and held it in 1 quarter. The position peaked at $31K in Q1 2021. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • Eudaimonia Partners reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 254 CRISPR Therapeutics shares in Q2 2021, an estimated $31K.
  • Eudaimonia Partners first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's CRISPR Therapeutics position peaked at $31K in Q1 2021.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.